Risk assessment of indeterminate lung nodule characterization by a novel plasma-protein multiplexed assay in current smokers: Results of a clinical experience program
R. Arfoosh, K. Nguyen, Amanda L. Fish, V. Wells, Denise Rebeor, A. Seger, M. Beggs, Gregory G Allen, R. El-Bizri, Richard Torricelli, DeEtta DeBault, A. Vallejo, J. Medina, Rana Hasan, K. Melby, D. Miller, Bryce Cowgill, Thomas DeMarini
{"title":"Risk assessment of indeterminate lung nodule characterization by a novel plasma-protein multiplexed assay in current smokers: Results of a clinical experience program","authors":"R. Arfoosh, K. Nguyen, Amanda L. Fish, V. Wells, Denise Rebeor, A. Seger, M. Beggs, Gregory G Allen, R. El-Bizri, Richard Torricelli, DeEtta DeBault, A. Vallejo, J. Medina, Rana Hasan, K. Melby, D. Miller, Bryce Cowgill, Thomas DeMarini","doi":"10.15761/brr.1000128","DOIUrl":null,"url":null,"abstract":"Background: To reduce overdiagnosis and overtreatment of non-cancerous pulmonary nodules found on chest imaging, an accurate non-invasive and easily administered test is needed to assist in the detection and diagnosis of cancers in a cost-effective manner at an early stage, when curative interventions are still possible. Objective: To assess the results of a novel, plasma-based multiplexed protein assay in a clinical experience program. Methods: Fifty-four consecutive plasma samples were evaluated in a CLIA-certified laboratory using the novel blood test. All samples were from patients who are current smokers, aged 25 years and older, and have an indeterminate pulmonary nodule 0.4 to 3 cm in diameter. Results: The mean patient age was 65.5 years and the mean nodule size was 1.0 cm. 26 patients were male (52% female). Of the 54 tests, the assay results for 23 individuals were determined to be in the lower risk of malignancy range (score ≤49). 42 patients had a pre-test probability in the intermediate risk range as calculated by the VA Clinical Model. Of those patients, the assay characterized 22 as having a lower risk of malignancy (52%). Conclusion: The risk stratification of individuals with an indeterminate pulmonary nodule appears to be enhanced by identifying benign nodules compared to current methods in clinical practice. We hypothesize patients with benign disease may benefit the most from this assay by avoiding unnecessary subsequent overtreatment such as lung biopsy or bronchoscopy, while improving patient quality of care and reducing associated risks and costs from these procedures. Providers and their patients in whom they suspect lung cancer may consider using this novel assay prior to proceeding with more aggressive interventions. *Correspondence to: Amanda L Fish, MagArray Inc, Milpitas CA, USA, E-mail: Amanda.Fish@magarray.com","PeriodicalId":92337,"journal":{"name":"Biomedical research and reviews","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedical research and reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15761/brr.1000128","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: To reduce overdiagnosis and overtreatment of non-cancerous pulmonary nodules found on chest imaging, an accurate non-invasive and easily administered test is needed to assist in the detection and diagnosis of cancers in a cost-effective manner at an early stage, when curative interventions are still possible. Objective: To assess the results of a novel, plasma-based multiplexed protein assay in a clinical experience program. Methods: Fifty-four consecutive plasma samples were evaluated in a CLIA-certified laboratory using the novel blood test. All samples were from patients who are current smokers, aged 25 years and older, and have an indeterminate pulmonary nodule 0.4 to 3 cm in diameter. Results: The mean patient age was 65.5 years and the mean nodule size was 1.0 cm. 26 patients were male (52% female). Of the 54 tests, the assay results for 23 individuals were determined to be in the lower risk of malignancy range (score ≤49). 42 patients had a pre-test probability in the intermediate risk range as calculated by the VA Clinical Model. Of those patients, the assay characterized 22 as having a lower risk of malignancy (52%). Conclusion: The risk stratification of individuals with an indeterminate pulmonary nodule appears to be enhanced by identifying benign nodules compared to current methods in clinical practice. We hypothesize patients with benign disease may benefit the most from this assay by avoiding unnecessary subsequent overtreatment such as lung biopsy or bronchoscopy, while improving patient quality of care and reducing associated risks and costs from these procedures. Providers and their patients in whom they suspect lung cancer may consider using this novel assay prior to proceeding with more aggressive interventions. *Correspondence to: Amanda L Fish, MagArray Inc, Milpitas CA, USA, E-mail: Amanda.Fish@magarray.com
背景:为了减少在胸部影像学上发现的非癌性肺结节的过度诊断和过度治疗,需要一种准确的、无创的、易于实施的检查,以经济有效的方式在早期阶段帮助发现和诊断癌症,当治疗干预仍然是可能的。目的:在临床经验项目中评估一种新型的、基于血浆的多重蛋白测定的结果。方法:在clia认证的实验室使用新型血液检测对54份连续血浆样本进行评估。所有样本均来自年龄在25岁及以上的吸烟者,并且有一个直径0.4至3cm的不确定肺结节。结果:患者平均年龄65.5岁,平均结节大小1.0 cm。男性26例(女性52%)。在54项检测中,23人的检测结果被确定为恶性肿瘤风险较低(评分≤49)。根据VA临床模型计算,42例患者的预测概率在中间风险范围内。在这些患者中,有22例具有较低的恶性肿瘤风险(52%)。结论:在临床实践中,与目前的方法相比,通过识别良性结节,不确定肺结节个体的风险分层似乎得到了加强。我们假设良性疾病的患者可能从该检测中获益最多,因为它避免了不必要的后续过度治疗,如肺活检或支气管镜检查,同时提高了患者的护理质量,降低了这些手术的相关风险和成本。提供者和他们怀疑肺癌的患者可以考虑在进行更积极的干预之前使用这种新的检测方法。*收件人:Amanda L Fish, MagArray Inc, Milpitas CA, USA, E-mail: Amanda.Fish@magarray.com